Breaking Finance News

Akebia Therapeutics Inc (NASDAQ:AKBA) target price raised to $18.00, reported today by Brean Murray

Akebia Therapeutics Inc (NASDAQ:AKBA) had its target price raised to $18.00 by Brean Murray in a report released Thursday September 29, 2016. The new target price indicates a possible upside of 0.98% based on the company's last stock close price.

Previously on 3/15/2016, H.C. Wainwright reported about Akebia Therapeutics Inc (NASDAQ:AKBA) lowered the target price from $25.00 to $18.00. At the time, this indicated a possible upside of 1.05%.

Yesterday Akebia Therapeutics Inc (NASDAQ:AKBA) traded 0.00% even at $9.08. The company’s 50-day moving average is $8.43 and its 200-day moving average is $8.62. The last stock close price is up 5.38% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 0 shares of the stock were exchanged, down from an average trading volume of 190,783

See Chart Below

Akebia Therapeutics Inc (NASDAQ:AKBA)

Akebia Therapeutics Inc has a 52 week low of $7.00 and a 52 week high of $13.20 The company’s market cap is currently $0.

In addition to Brean Murray reporting its target price, a total of 7 firms have reported on the stock. The consensus target price is $18.29 with 1 firm rating the stock a strong buy, 5 firms rating the stock a buy, 1 firm rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Akebia Therapeutics Inc (NASDAQ:AKBA)

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics based on hypoxia inducible factor (HIF) biology, and the commercialization of these products for patients with serious medical needs. The Company's segment is the business of developing and commercializing proprietary therapeutics based on HIF biology. The Company is involved in developing its lead product candidate, vadadustat, as an oral therapy for the treatment of anemia in chronic kidney disease (CKD) subjects not on dialysis and in subjects on dialysis. Its other clinical candidate, AKB-6899, is designed as a small molecule HIF prolyl-hydroxylase (HIF-PH) inhibitor with therapeutic benefit in oncology and ophthalmology. The Company is engaged in conducting approximately two global Phase III studies for the treatment of anemia in non-dialysis dependent patients, and over two Phase III studies for the treatment of anemia in dialysis-dependent CKD patients.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.